{"id":"https://openalex.org/W2062679938","doi":"https://doi.org/10.1517/14656566.4.5.779","title":"Colesevelam HCl: a non-systemic lipid-altering drug","display_name":"Colesevelam HCl: a non-systemic lipid-altering drug","alternate_titles":[],"publication_year":2003,"publication_date":"2003-01-01","ids":{"openalex":"https://openalex.org/W2062679938","doi":"https://doi.org/10.1517/14656566.4.5.779","mag":"2062679938","pmid":"https://pubmed.ncbi.nlm.nih.gov/12740000"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.4.5.779","doi":"https://doi.org/10.1517/14656566.4.5.779","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.4.5.779","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2062679938"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053191013","display_name":"Harold Edward Bays","orcid":"https://orcid.org/0000-0001-9912-1408","observed_orcids":["https://orcid.org/0000-0001-9912-1408"]},"institutions":[{"id":"https://openalex.org/I4210124370","display_name":"Radiant Research (United States)","ror":"https://ror.org/03fz1e596","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124370"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Harold Bays","raw_affiliation_strings":["Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 12200 W 106th, Overland Park, KS 66215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 12200 W 106th, Overland Park, KS 66215, USA","institution_ids":["https://openalex.org/I4210124370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048442493","display_name":"Carlos A. Dujovne","orcid":"https://orcid.org/0000-0002-8376-3198","observed_orcids":["https://orcid.org/0000-0002-8376-3198"]},"institutions":[{"id":"https://openalex.org/I4210124370","display_name":"Radiant Research (United States)","ror":"https://ror.org/03fz1e596","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124370"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Carlos Dujovne","raw_affiliation_strings":["Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 12200 W 106, USA. carlosdujovne@radiantresearch.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 12200 W 106, USA. carlosdujovne@radiantresearch.com","institution_ids":["https://openalex.org/I4210124370"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210124370"],"apc_list":null,"apc_paid":null,"fwci":1.0793,"has_fulltext":false,"cited_by_count":108,"citation_normalized_percentile":{"value":0.75426621,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"4","issue":"5","first_page":"779","last_page":"790"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/colesevelam","display_name":"colesevelam","score":0.9449999928474426},{"id":"https://openalex.org/keywords/bile-acid-sequestrants","display_name":"bile acid sequestrants","score":0.9470000267028809},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.7039999961853027},{"id":"https://openalex.org/keywords/hdl-cholesterol","display_name":"HDL cholesterol","score":0.9769999980926514},{"id":"https://openalex.org/keywords/statin-intolerance","display_name":"statin intolerance","score":0.8579999804496765},{"id":"https://openalex.org/keywords/statin-adverse-effects","display_name":"statin adverse effects","score":0.7480000257492065},{"id":"https://openalex.org/keywords/statin-drug-interactions","display_name":"statin-drug interactions","score":0.6970000267028809},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.7850000262260437},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.9760000109672546},{"id":"https://openalex.org/keywords/combination-lipid-lowering-therapy","display_name":"combination lipid-lowering therapy","score":0.7929999828338623},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.656000018119812}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8302873969078064},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6162748336791992},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.5903433561325073},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5893124938011169},{"id":"https://openalex.org/C2779399885","wikidata":"https://www.wikidata.org/wiki/Q413288","display_name":"Bile acid","level":2,"score":0.5490021705627441},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.512367844581604},{"id":"https://openalex.org/C2777300911","wikidata":"https://www.wikidata.org/wiki/Q692536","display_name":"Myopathy","level":2,"score":0.43881407380104065},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4282534718513489},{"id":"https://openalex.org/C2779379848","wikidata":"https://www.wikidata.org/wiki/Q917069","display_name":"Rhabdomyolysis","level":2,"score":0.4201889932155609},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41794878244400024},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.20641061663627625}],"mesh":[{"descriptor_ui":"D000069472","descriptor_name":"Colesevelam Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000499","descriptor_name":"Allylamine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000499","descriptor_name":"Allylamine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000499","descriptor_name":"Allylamine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000499","descriptor_name":"Allylamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1517/14656566.4.5.779","doi":"https://doi.org/10.1517/14656566.4.5.779","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.4.5.779","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"doi:10.1517/eoph.4.5.779.22219","doi":"https://doi.org/10.1517/eoph.4.5.779.22219","is_oa":false,"landing_page_url":"https://doi.org/10.1517/eoph.4.5.779.22219","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:12740000","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12740000","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1587435290","https://openalex.org/W1963611979","https://openalex.org/W1985163763","https://openalex.org/W2007976725","https://openalex.org/W2021042232","https://openalex.org/W2024334311","https://openalex.org/W2027101979","https://openalex.org/W2029471511","https://openalex.org/W2029833995","https://openalex.org/W2029963488","https://openalex.org/W2046991199","https://openalex.org/W2059078444","https://openalex.org/W2071802081","https://openalex.org/W2078260689","https://openalex.org/W2112534505","https://openalex.org/W2115621552","https://openalex.org/W2117030280","https://openalex.org/W2120194751","https://openalex.org/W2124639367","https://openalex.org/W2130873593","https://openalex.org/W2136512187","https://openalex.org/W2137781481","https://openalex.org/W2138282127","https://openalex.org/W2139353545","https://openalex.org/W2145799136","https://openalex.org/W2151602225","https://openalex.org/W2160945880","https://openalex.org/W2162155172","https://openalex.org/W2404315029","https://openalex.org/W2412473917","https://openalex.org/W4230285830","https://openalex.org/W4233165110","https://openalex.org/W4238251256","https://openalex.org/W4239263566","https://openalex.org/W4245747504","https://openalex.org/W4249825849"],"related_works":["https://openalex.org/W2124639367","https://openalex.org/W4239263566","https://openalex.org/W2007255634","https://openalex.org/W2014844608","https://openalex.org/W2032035573","https://openalex.org/W2070340881","https://openalex.org/W2062086873","https://openalex.org/W2060270653","https://openalex.org/W2162155172"],"abstract_inverted_index":{"Colesevelam":[0,207],"HCl":[1,60,174,208],"(WelChol,":[2],"Sankyo":[3],"Pharmaceuticals":[4],"Inc.)":[5],"is":[6,43,57,94,155,191],"a":[7,66,176,185],"bile":[8,47,54],"acid":[9,48],"sequestrant":[10],"polymer,":[11],"which":[12],"has":[13,65],"been":[14],"shown":[15],"to":[16,45,104,180,194,234],"significantly":[17],"lower":[18],"low":[19],"density":[20],"lipoprotein":[21,27],"cholesterol":[22,28],"and":[23,33,56,111,135,169,242],"favourably":[24],"affect":[25],"high-density":[26],"blood":[29,120],"levels":[30],"in":[31,34,50,62,115,159,164,199,214,225],"monotherapy":[32,154,215],"combination":[35,189],"with":[36,75,81,140,201,219],"statins":[37,84,145],"(HMG-CoA":[38],"reductase":[39],"inhibitors).":[40],"Although":[41],"it":[42,52,64,93],"similar":[44],"other":[46,181],"sequestrants":[49],"that":[51,63,70,97,107],"binds":[53],"acids":[55],"non-systemic,":[58],"colesevelam":[59,173],"differs":[61],"unique":[67],"polymer":[68],"structure":[69],"allows":[71],"for":[72,216],"greater":[73],"tolerability":[74],"less":[76],"potential":[77,149,229],"drug":[78,150],"interactions":[79],"than":[80],"resins.":[82],"Currently,":[83],"are":[85,108],"the":[86,170],"most":[87],"commonly":[88],"prescribed":[89],"lipid-altering":[90,177,182,236],"drugs.":[91,183],"However,":[92],"not":[95,157],"uncommon":[96],"patients":[98,168,200,218,227],"demonstrate":[99],"true":[100],"or":[101,117,122,124,204],"perceived":[102],"intolerances":[103],"statin":[105,153],"therapy,":[106],"often":[109,156,192],"dose-related":[110],"may":[112,209],"include":[113],"elevations":[114],"liver":[116],"muscle":[118,125,128],"enzyme":[119,129],"levels,":[121],"myalgias":[123],"weakness":[126],"without":[127],"elevation.":[130],"In":[131,142],"rare":[132],"circumstances,":[133],"myopathy":[134],"even":[136],"rhabdomyolysis":[137],"can":[138],"occur":[139],"statins.":[141],"addition,":[143],"many":[144,165,217],"also":[146,210],"have":[147],"important":[148],"interactions.":[151],"Finally,":[152],"sufficient":[158],"achieving":[160],"lipid":[161],"treatment":[162,178,196],"goals":[163,197],"severely":[166],"dyslipidaemic":[167],"availability":[171],"of":[172],"provides":[175],"addition":[179],"From":[184],"clinical":[186],"perspective,":[187],"such":[188],"therapy":[190],"required":[193],"achieve":[195],"[1]":[198],"more":[202],"complicated":[203],"severe":[205],"dyslipidaemia.":[206],"be":[211],"an":[212],"alternative":[213,235],"mild-to-moderate":[220],"hypercholesterolaemia,":[221],"as":[222,224,239],"well":[223],"some":[226],"at":[228],"risk":[230],"from":[231],"systemic":[232],"exposure":[233],"drugs":[237],"(such":[238],"young":[240],"children":[241],"fertile":[243],"women).":[244]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2062679938","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
